citalopram Articles
Forest agrees to guilty plea for violating FDA laws and pay over $300 million in penalties
16 September 2010
Forest accused of illegal promotion
9 March 2009
Targacept to advance drug into clinicals
29 October 2007
SSRIs lower BMD in men and women
2 July 2007
Forest records $238M loss for fiscal 4th-qtr
7 May 2007
Forest Labs 4th-qtr profit jumps 28%
29 January 2007
Targacept's TRIDMAC improves on Celexa
20 November 2006
US FDA posts DSOB meeting summary
15 August 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Forest Labs' sales hit by Celexa competition
25 April 2005
Stock Commentary - New York
18 April 2005
Forest Labs cuts earnings forecast
11 April 2005
Forest disappoints, despite 17% EPS hike
24 January 2005
Forest beats 2nd-qtr targets; raises outlook
25 October 2004
Stock Commentary - New York week to Oct 4
11 October 2004
Forest raises fiscal 2005 2nd-qtr earnings estimate
11 October 2004
Forest pursues new use for Lexapro
6 September 2004
IVAX response to Australia patent news
30 August 2004
Merck KGaA lifts 2004 forecast on strong qtr
2 August 2004
Stock Commentary - New York
28 June 2004
Letter from the Editor
28 June 2004
Stock Commentary - New York
7 June 2004
Merck KGaA's organic pharma sales up 4.3%
3 May 2004
Forest posts 20% jump in fiscal-2003 sales
3 May 2004
Lexapro as effective as Paxil for GAD
22 March 2004
Forest subpoenaed over Celexa
9 February 2004
Forest profit boosted by antidepressants
26 January 2004
Lexapro cleared for new use by FDA
5 January 2004
Positive new data for Forest's Lexapro
22 December 2003
Lundbeck issues profit warning; shares slump on antidepressant woes
10 November 2003
Forest/Lundbeck file suit against IVAX
29 September 2003
IVAX applies to FDA for generic Lexapro
18 August 2003
Lexapro offsets Celexa for Forest's 2nd-qtr
21 July 2003
Forest seeks approval for Lexapro in panic
12 May 2003
Antidepressant sales boost Forest in 4th qtr
28 April 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Lunbeck acquires Synaptic in $122M deal
17 March 2003
Antidepressants drive Forest's profits upward
27 January 2003
Forest Labs raises earnings estimate
6 January 2003
Forest's lercanidipine approvable, says FDA
12 August 2002
Forest gets extension to Celexa protection in USA
22 July 2002
Forest Lab's Lexapro approvable in USA
3 June 2002
Brand name confusion "a risk for patients"
27 May 2002
Celexa drives growth at Forest Labs
6 May 2002
Net income up 33% at Forest Labs.
21 January 2002
Lundbeck's Cipralex cleared in Switzerland
14 January 2002
Lundbeck earnings soar as citalopram sales continue to increase
7 November 2001
Launch of Lundbeck's Cipralex delayed?
19 September 2001
Celexa driving earnings at Forest
19 July 2001
Merckle unveils Phase II data on coxib rival
21 June 2001
Cipramil sales driving Lundbeck growth
16 May 2001
Forest's successor to Celexa more effective
11 May 2001
Forest filed for Celexa follow-up in USA
26 March 2001
Single-isomer Celexa filed next year?
14 December 2000
Mitsui gains certain rights to Celexa in Japan
7 September 2000
Huge earnings rise at Denmark's Lundbeck
16 August 2000
45% 2nd qtr sales boost for Forest Labs
20 July 2000
Lundbeck gains share of US antidepressant market
21 June 2000
Lundbeck 1st-qtr turnover climbs 36%
25 May 2000
Forest Labs' S-citalopram
17 May 2000
Lundbeck set to defend citalopram
16 May 2000
Lundbeck upgraded on citalopram outlook
6 April 2000
Lundbeck profits up 108%, thanks to Celexa
29 February 2000
How the smaller firm can get the most out of its sales force
24 February 2000
GS revises Lundbeck earnings forecasts
24 January 2000
FDA approves oral Celexa
11 January 2000
Forest Labs applies for listing on NYSE
30 September 1999
Pfizer/Monsanto act on drug name confusion
1 September 1999
Celexa driving Lundbeck profits
18 August 1999
Lundbeck starts S-citalopram pivotal studies
27 May 1999
Lundbeck looking to list on Copenhagen SE
20 May 1999
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
